News

May 20th, 2020

Presentation of “SPI2” Phase III Results at the EAN Virtual Congress 2020
Read more

March 10th, 2020

MedDay Reports Top-Line Data from Phase III Trial “SPI2” for Treatment of Progressive Forms of Multiple Sclerosis
Read more

December 12th, 2019

MedDay Reports Last Patient Study Visit in Second Phase 3 Clinical Trial with MD1003®, an Important Milestone Towards Completion of the SPI2 Study in Progressive Multiple Sclerosis
Read more

July 22nd, 2019

MedDay Pharmaceuticals to webcast key opinion leader meeting on new treatment strategies for progressive forms of multiple sclerosis tomorrow
Read more
See all recent news
Events
October 03 2019

MedDay attends the 32nd congress of "Association des Neurologues Libéraux de Langue française" (ANLLF) in Strasbourg, France

September 11 2019

MedDay attends the 35th congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Stockholm, Sweden. Excited to meet you on our booth C60!

June 29 2019

MedDay attends the 5th congress of the European Academy of Neurology (EAN) in Oslo, Norway. Meet us Booth C34!

May 28 2019

MedDay attends the 2019 Consortium of Multiple Sclerosis Centers (CMSC) Meeting in Seattle, Washington. Meet us at our booth!

April 16 2019

MedDay attends les "Journées de Neurologie de Langue Française" (JNLF) 2019 in Lille, France

See all events